Skye Bioscience (SKYE) Other Accumulated Expenses (2018 - 2026)

Skye Bioscience (SKYE) has reported Other Accumulated Expenses for 9 consecutive years, with $3.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 294.82% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $3.3 million (up 294.82% YoY), while the FY2025 annual figure was $2.6 million, up 304.13% from the prior year.
• Other Accumulated Expenses rose to $3.3 million in Q1 2026 per SKYE's latest filing, from $2.6 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $3.3 million in Q1 2026 and bottomed at $95850.0 in Q4 2022.
• Historically, Other Accumulated Expenses has averaged $1.6 million across 5 years, with a median of $1.1 million in 2023.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses tumbled 74.5% — and 2023, when it surged 934.75%.
• Skye Bioscience's Other Accumulated Expenses stood at $95850.0 in 2022, then soared by 934.75% to $991805.0 in 2023, then slumped by 34.04% to $654201.0 in 2024, then soared by 304.13% to $2.6 million in 2025, then increased by 26.62% to $3.3 million in 2026.
• Business Quant data shows SKYE's Other Accumulated Expenses at $3.3 million in Q1 2026, $2.6 million in Q4 2025, and $2.4 million in Q3 2025.